middle.news
How Cleo Diagnostics Is Revolutionising Ovarian Cancer Testing with Bio-Techne’s Ella™
9:54am on Wednesday 18th of February, 2026 AEDT
•
Healthcare
Read Story
How Cleo Diagnostics Is Revolutionising Ovarian Cancer Testing with Bio-Techne’s Ella™
9:54am on Wednesday 18th of February, 2026 AEDT
Key Points
Selection of Bio-Techne’s automated Ella™ ELISA platform for test development
Improved assay speed, sensitivity, and automation over traditional methods
Progressing towards binding agreement for analytical validation and clinical trial testing
Data from validation to support pivotal FDA 510(k) submission
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CLEO DIAGNOSTICS (ASX:COV)
OPEN ARTICLE